Prospects Fund

Prospects Oncology Fund

prospect-oncology-fund-imgFACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Investment Strategy and have the potential to act as deal flow for the IPDC Fund. Awarded grants typically range between $50,000 and $200,000.

Funding is governed by a research contract which grants certain rights to FACIT.   FACIT receives no financial consideration on Prospects grants under $90,000.  On grants of $100,000 or more, FACIT receives an option to make an investment at the IPDC level and act as the agent for commercialization.  If the option is exercised, funding received from the Prospects grant will be credited towards FACIT's IPDC investment.

How to apply:

The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:

  • March 31
  • September 30

The pre-submission form can be downloaded here.

Late applications will not be considered.

Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.

Select Prospects Funded Projects

Prospects Fund (Other)

Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation

Further development of promising potent compounds in triple-negative breast cancer models.

Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell ProliferationInhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation


Universal CAR-T Therapy

Development of a universally compatible (allogeneic) source for the next generation of CAR-T therapies based on hematopoietic stem cells harvested from healthy donors.

Universal CAR-T TherapyUniversal CAR-T Therapy


ADC Linker Platform

Further development of novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC).

ADC Linker PlatformADC Linker Platform


Test to Predict Breast Cancer Patient Response to Anthracyclines

Further validation of novel diagnostic gene test to predict which patients benefit from anthracycline chemotherapy.

Test to Predict Breast Cancer Patient Response to AnthracyclinesTest to Predict Breast Cancer Patient Response to Anthracyclines


View All Prospects Funded Projects